Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study
by
, , ,
Hrvoje Kaučić
1,2,*
,
Domagoj Kosmina
1,
Dragan Schwarz
1,3,4,
Andreas Mack
5,
Hrvoje Šobat
1,
Adlan Čehobašić
1,2,
Vanda Leipold
1,2,
Iva Andrašek
1,
Asmir Avdičević
1 and
Mihaela Mlinarić
1 1
Specijalna bolnica Radiochirurgia Zagreb, Ulica Dr. Franje Tuđmana 4, 10431 Sveta Nedelja, Croatia
2
Sveučilište Josipa Jurja Strossmayera u Osijeku—Medicinski Fakultet Osijek, Josipa Huttlera 4, 31000 Osijek, Croatia
3
Medicinski Fakultet Sveučilišta u Rijeci, Braće Branchetta 20/1, 51000 Rijeka, Croatia
4
Sveučilište Josipa Jurja Strossmayera u Osijeku—Fakultet za Dentalnu Medicinu i Zdravstvo Osijek, Crkvena Ulica 21, 31000 Osijek, Croatia
5
Swiss NeuroRadiosurgery Center, Bürglistrasse 29, 8002 Zürich, Switzerland
*
Author to whom correspondence should be addressed.
Cancers 2022, 14(11), 2688; https://doi.org/10.3390/cancers14112688
Submission received: 20 April 2022
/
Revised: 24 May 2022
/
Accepted: 27 May 2022
/
Published: 29 May 2022
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Pancreatic Cancer)
Simple Summary
An estimated 30–40% of patients with pancreatic cancer are at an unresectable locally advanced stage at the time of diagnosis, and this represents a particular problem in oncology due to the challenges in local treatment. The aim of this study was to investigate the potentially positive impact of local dose escalation during stereotactic ablative radiotherapy using intrafractional fiducial-based motion management on clinical outcomes. The system used for motion management in our study was Calypso® Extracranial Tracking, and this is the first reported application of this system for locally advanced pancreatic cancer. Using very narrow safety margins around the lesion during the treatment, we were able to effectively spare surrounding healthy organs and safely apply median biological effective dose of 112.5 Gy. This approach, especially when combined with systemic therapy, resulted in very favourable one-year local tumor control of 100% and median overall survival of 24 months, with no grade > 2 toxicities.
Abstract
(1) Background: The aim of this study was to evaluate the efficacy and safety of SABR for LAPC using Calypso® Extracranial Tracking for intrafractional, fiducial-based motion management, to present this motion management technique, as there are yet no published data on usage of Calypso® during SABR for LAPC, and to report on our clinical outcomes. (2) Methods: Fifty-four patients were treated with SABR in one, three, or five fractions, receiving median BED10 = 112.5 Gy. Thirty-eight patients received systemic treatment. End points were OS, FFLP, PFS, and toxicity. Actuarial survival analysis and univariate analysis were investigated. (3) Results: Median follow-up was 20 months. Median OS was 24 months. One-year FFLP and one-year OS were 100% and 90.7%, respectively. Median PFS was 18 months, and one-year PFS was 72.2%. Twenty-five patients (46.3%) were alive at the time of analysis, and both median FU and OS for this subgroup were 26 months. No acute/late toxicity > G2 was reported. (4) Conclusions: SABR for LAPC using Calypso® presented as an effective and safe treatment and could be a promising local therapeutic option with very acceptable toxicity, either as a single treatment or in a multimodality regimen. Dose escalation to the tumor combined with systemic treatment could yield better clinical outcomes.
